| Literature DB >> 19888340 |
Ingibjörg H Jonsdottir1, Daniel A Hägg, Kristina Glise, Rolf Ekman.
Abstract
BACKGROUND: Psychosocial stress is becoming a major contributor to increased mental ill-health and sick leave in many countries. Valid markers of chronic stress would be valuable for diagnostic and prognostic purposes. A recent study suggested monocyte chemotactic protein-1 (MCP-1), epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF) as markers of chronic stress. We aimed to confirm these potential biomarkers of prolonged psychosocial stress in female patients. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2009 PMID: 19888340 PMCID: PMC2766003 DOI: 10.1371/journal.pone.0007659
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Diagnostic criteria for Exhaustion Disorder according to The National Insurance Board in Sweden.
|
| Physical and mental symptoms of exhaustion with minimum two weeks duration. The symptoms have developed in response to one or more identifiable stressors which have been present for at least 6 months. |
|
| Markedly reduced mental energy, which is manifested by reduced initiative, lack of endurance, or increase of time needed for recovery after mental efforts. |
|
| At least four of the following symptoms have been present most of the day, nearly every day, during the same 2-week period: |
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
| The symptoms cause clinically significant distress or impairment in social, occupational or other important areas of functioning. |
|
| The symptoms are not due to the direct physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical condition (e.g. hypothyroidism, diabetes, infectious disease). |
|
| If criteria for major depressive disorder, dysthymic disorder or generalized anxiety disorder are met, exhaustion disorder is set a co-morbid condition. |
Descriptive data of patients and healthy controls, all females, included in the first part of the study (cytokine and growth factors measurements).
| Patients (n = 42) | Controls (n = 42) | p-value | |
|
| 42.1±9.4 | 42.7±7.5 | 0.664 |
|
| 23.1±3.0 | 23.4±2.6 | 0.371 |
|
| 5.4±0.81 | 2.6±1.22 | <0.001 |
| - Percent scoring >4.3 on burnout | 88% | 13% | |
|
| 74% | 0% | |
|
| |||
|
| 64% | 0% | |
|
| |||
|
| <0.001 | ||
| 0–6 | 36% | 91% | |
| 7–10 | 36% | 2% | |
| >10 | 29% | 7% | |
|
| <0.001 | ||
| 0–6 | 5% | 74% | |
| 7–10 | 21% | 14% | |
| >10 | 74% | 12% |
Mann-Whitney test, data presented as mean and SD.
Chi-square test, data presented as percentage within each scoring group.
Descriptive data for subjects included in the second part of the study (CRP measurement).
| Patients (n = 89) | Controls (n = 88) | p-value | |
|
| 40.9±6.7 | 44.6±8.5 | 0.006 |
|
| 48% | 50% | 0.822 |
|
| 24.3±3.0 | 23.7±2.4 | 0.198 |
|
| 5.3±0.85 | 2.3±0.88 | <0.001 |
| - Percent scoring >4.3 on burnout | 92% | 6% | |
|
| 73% | 0% | |
|
| |||
|
| 75% | 0% | |
|
| |||
|
| <0.001 | ||
| 0–6 | 34% | 94% | |
| 7–10 | 33% | 6% | |
| >10 | 32% | 0% | |
|
| <0.001 | ||
| 0–6 | 11% | 83% | |
| 7–10 | 24% | 11% | |
| >10 | 64% | 6% |
Mann-Whitney test, data presented as mean and SD.
Chi-square test, data presented as percentage within each scoring group.
Plasma levels (pg/ml) of MCP-1, VEGF and EGF in relation to Exhaustion disorder (ED) diagnosis, degree of burnout, anxiety and depression in female patients and healthy controls.
| Control | Patient | Burnout | Burnout | Anxiety | Anxiety | Depression | Depression | |
| <4.3 | ≥4.3 | score ≤10 | score >10 | score ≤10 | score >10 | |||
|
| 115±18.6 | 117±7.49 | 111±18.7 | 122±7.43 | 119±15.8 | 102±8.67 | 118±11.9 | 92.3±12.0 |
| (42) | (41) | (42) | (41) | (49) | (34) | (68) | (15) | |
| p = 0.771 | p = 0.978 | p = 0.083 | p = 0.091 | |||||
|
| 5.93±1.03 | 6.31±5.04 | 6.47±1.07 | 5.42±5.08 | 5.12±1.02 | 8.37±5.23 | 5.54±1.35 | 7.11±8.70 |
| (25) | (19) | (25) | (19) | (26) | (18) | (34) | (10) | |
| p = 0.696 | p = 0.991 | p = 0.272 | p = 0.300 | |||||
|
| 8.98±6.20 | 11.6±1.54 | 10.6±5.99 | 10.4±1.62 | 9.23±5.26 | 10.7±1.76 | 11.3±3.73 | 9.03±1.99 |
| (33) | (37) | (34) | (36) | (39) | (31) | (56) | (14) | |
| p = 0.259 | p = 0.747 | p = 0.332 | p = 0.445 |
Data are presented as median and standard error of the mean (SEM).
Due to the high number of non-detectable values, the number of observations varies and is listed within parenthesis for each measurement.
P values are given for respective analysis between the groups.
Figure 1Plasma levels of MCP-1 and VEGF using different platforms.
Plasma levels of MCP-1 (n = 83) and VEGF (N = 65) from patients and healthy controls measured using two different analysing methods. Using the MSD platform yielded significantly higher levels of both MCP-1 (2.1-fold) and VEGF (3.7-fold) compared to the RANDOX platform. Data are presented as median and SEM. *** p<0.001
Figure 2Serum levels of CRP.
Serum levels of inflammatory marker CRP were significantly higher (1.4-fold) in patients with Exhaustion Disorder (n = 89) compared with control subjects (n = 88). Data presented as median and SEM. * p = 0.02